The oncogenic effect of TARBP2 has also been reported in metastatic breast cancer indicating that the overexpression of TARBP2 destabilizes amyloid precursor proteins (APPs) and ZNF395 transcripts containing TARBP2-binding structural elements (TBSEs), thereby leading to the degradation of metastasis-suppressor transcripts associated with Alzheimer’s and Huntington’s disease, respectively [7]. This evidence concerns the gene ZNF395 and juvenile Huntington disease.